about
Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy.NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Tumor clone dynamics in lethal prostate cancerSerial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug AdministrationAllelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomasbc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analysesLapatinib in metastatic breast cancer.Eribulin mesylate for the treatment of late-stage breast cancer.What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?Olaparib for the treatment of breast cancer.Vinflunine for the treatment of breast cancer.Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases.[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.[Prognostic and predictive factors for gliomas in adults].Pulse oximetry and high-dose vasopressors: a comparison between forehead reflectance and finger transmission sensors.Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer.Emotional distress and subjective impact of the disease in young women with breast cancer and their spouses.Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).Efficacy of buparlisib in treating breast cancer.[Tumor resistance to HER2 inhibitors: the drug sedimentation concept].[Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases].Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.P20.01 MEVITEM: A European, randomized, open-label Phase I/II study of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent or refractory medulloblastoma presenting an activation of the Sonic HedgehoEmerging PARP inhibitors for treating breast cancerAn Update on the Clinical Use of CDK4/6 Inhibitors in Breast CancerThe self-reported perceptions of the repercussions of the disease and its treatments on daily life for young women with breast cancer and their partnersLetrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancerPrognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 cases[The role of interval surgery in the treatment's strategy of advanced ovarian cancer]Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series[Unusual antenatal gestational choriocarcinoma]5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French studyPharmacokinetic drug evaluation of abemaciclib for advanced breast cancerPatient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancerPertuzumab for the treatment of breast cancermiR-370-3p Is a Therapeutic Tool in Anti-glioblastoma Therapy but Is Not an Intratumoral or Cell-free Circulating BiomarkerQLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA
P50
Q33656801-EE0E0EB3-DB44-4ED9-A062-72BDB0594855Q33987977-1281CA4E-B45E-4636-8A7B-AB675615F845Q35575930-59945C2D-7795-41B7-A6FC-FC71D2F18CFCQ36087929-9FF2A85A-24A2-42EC-B913-006EED61BBE3Q36196936-3B9D80FD-1D36-4497-BB07-855B4A751805Q36543286-7B64B673-0411-443B-87B2-68F31D267EBDQ37622978-1A114171-CCFB-4A77-9DCA-D733EC1ED862Q37956659-0A7459BA-444B-4B9B-9AF8-98B202A5337AQ37982444-3B17AB2A-C0FF-46D6-B0A7-98BA2576F6D7Q38843992-D3921CB0-329A-4B17-AB17-B62475DA7D89Q38916189-0EABDC79-A4D1-465A-BA67-68F1B54871B8Q39775271-8E7EF5E1-BC5D-45A7-8C46-E1AB7EF742A9Q40764920-7DA92121-083B-48AB-829A-B2B7142F2FEAQ42695216-DC8014F3-B86B-47CB-81BA-9249FD79A7F0Q43180037-245A4E5B-13DA-4D6F-B67D-7347D8A58FF6Q44754640-A90C1718-34D9-4EBA-B222-3D7E99949DC2Q46056045-61F11345-0E07-4EDA-8EA5-FAC62142AEE6Q47297770-829A1470-C500-4241-8A90-B2FC0ADBD40BQ47299171-19CDEEB8-B4D9-4814-A18E-42E6F19CE4F1Q47389877-26E226A7-01D7-4389-A6E4-9B4AEBDD83C3Q48770246-3E6E3317-45E9-4556-82AE-B54718E8D348Q49711965-E88BDA32-5CF7-45F5-9E26-451D1FA8BF6CQ52300867-40EA49BF-5DF9-4474-9A56-33D49985FD2EQ53143409-BF43A285-A1EC-405F-9A83-658F3E81589AQ54317605-2EBD0628-7635-4E20-AFE1-24FD9A5EA517Q54965819-12CF3030-C4FD-4E0C-8C70-74D69EA6B9ADQ57105640-B051832F-8AC5-4589-8584-F92F46EB794FQ57163370-135FFE25-B294-483C-B798-E224C34AD832Q57181425-033BF091-D54D-4A9D-AC04-50B184EC102CQ57279643-575E7003-2C23-46B0-92A4-2533FF50BA86Q58051892-0A1C5003-2E30-46A2-9090-279A55B92DD7Q83332596-7C0BA872-6716-4EA7-9CC4-C90ADD60D259Q85300328-A5B48F50-AE74-4EDC-AE9F-37BFFBBE7AE1Q85351167-16B8CDDC-837E-4D6F-967D-61707BADB0B2Q88293106-C2AFBE4C-2831-4FBD-B92E-43A3D85019B1Q90707375-0DF98AC8-2C5D-4425-89F9-85FF0B110E8CQ90858402-940AF8DA-7F36-4127-A453-FBEB3158F0DDQ92452462-F139F50F-1978-45C6-84FF-C7246BDCD9FDQ93370756-89A38317-4258-4AC2-910B-EC9E59847083Q94408305-7F05C923-21AC-45CA-9BD6-C994DFF39074
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-5273-0561
@en
name
Jean-Sébastien Frénel
@ast
Jean-Sébastien Frénel
@en
Jean-Sébastien Frénel
@nl
type
label
Jean-Sébastien Frénel
@ast
Jean-Sébastien Frénel
@en
Jean-Sébastien Frénel
@nl
prefLabel
Jean-Sébastien Frénel
@ast
Jean-Sébastien Frénel
@en
Jean-Sébastien Frénel
@nl
P106
P31
P496
0000-0002-5273-0561